Circassia starts Phase II allergy study
Circassia is conducting the study in the field of cat-dander allergy, and aims to complete the trial in the coming months. This clinical study builds on the results
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.